Sage Therapeutics said Monday that U.S. regulators accepted a marketing application for its rapid-acting antidepressant and granted it priority review with a decision date set for early August.
The Food and Drug Administration will assess the efficacy and safety of the Sage drug, a once-daily pill called zuranolone, for the treatment of people with major depressive disorder and postpartum depression.
Biogen owns half the commercial rights to zuranolone, for which it paid $1.5 billion to Sage in 2020.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect